Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy

Cathia Soulie, Maria Mercedes Santoro, Alexandre Storto, Basma Abdi, Charlotte Charpentier, Daniele Armenia, Aude Jary, Federica Forbici, Ada Bertoli, William Gennari, Massimo Andreoni, Cristina Mussini, Andrea Antinori, Carlo Federico Perno, Vincent Calvez, Francesca Ceccherini-Silberstein, Diane Descamps, Anne Genevieve Marcelin

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: Doravirine, a novel NNRTI, selects for specific mutations in vitro, including mutations at reverse transcriptase (RT) positions 106, 108, 188, 227, 230 and 234. The aim of this study was to examine the prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients. METHODS: Doravirine-associated resistance mutations identified in vitro or in vivo were studied in a set of 9199 HIV-1 RT sequences from HIV-1 antiretroviral-experienced patients, including 381 NNRTI-failing patients in France and Italy between 2012 and 2017. The following mutations were considered as resistance mutations: V106A/M, V108I, Y188L, G190S, F227C/L/V, M230I/L, L234I, P236L, K103N + Y181C, K103N + P225H and K103N + L100I. RESULTS: The frequencies of doravirine-associated resistance mutations (total dataset versus NNRTI-failing patients) were: V106A/M, 0.8% versus 2.6%; V108I, 3.3% versus 9.2%; Y188L, 1.2% versus 2.6%; G190S, 0.3% versus 2.1%; F227C/L/V, 0.5% versus 1.8%; M230I/L, 2.8% versus 0%; L234I, 0.1% versus 0.5%; K103N + Y181C, 3.9% versus 3.9%; K103N + P225H, 2.9% versus 4.7%; and K103N + L100I, 1.7% versus 3.9%, with a significantly higher proportion of these mutations in the NNRTI-failing group (P < 0.05), except for M230I/L and K103N + Y181C. The overall prevalence of sequences with at least one doravirine-associated resistance mutation was 12.2% and 34.9% in the total dataset and NNRTI-failing patients (P < 0.001), respectively. In comparison, the prevalence of the common NNRTI mutations V90I, K101E/P, K103N/S, E138A/G/K/Q/R/S, Y181C/I/V and G190A/E/S/Q were higher (8.9%, 7.9%, 28.6%, 12.6%, 14.2% and 8.9%, respectively). CONCLUSIONS: These results suggest that doravirine resistance in antiretroviral-experienced patients generally and specifically among NNRTI-failing patients is lower than resistance to other NNRTIs currently used, confirming its distinguishing resistance pattern.

Original languageEnglish
Pages (from-to)1026-1030
Number of pages5
JournalThe Journal of antimicrobial chemotherapy
Volume75
Issue number4
DOIs
Publication statusPublished - Apr 1 2020

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Soulie, C., Santoro, M. M., Storto, A., Abdi, B., Charpentier, C., Armenia, D., Jary, A., Forbici, F., Bertoli, A., Gennari, W., Andreoni, M., Mussini, C., Antinori, A., Perno, C. F., Calvez, V., Ceccherini-Silberstein, F., Descamps, D., & Marcelin, A. G. (2020). Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. The Journal of antimicrobial chemotherapy, 75(4), 1026-1030. https://doi.org/10.1093/jac/dkz553